Clinical trial
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II…
NCT00450229 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00450229 |
|---|---|
| Title | Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer |
| Official title | Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | diindolylmethane, placebo, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study |
| Enrollment | 45 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Mar 22, 2007 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: